Retatrutide TRIUMPH-1: 28.3% mean weight loss at 80 weeks on 12 mg vs 2.2% on placebo

Eli Lilly/Retatrutide

In the Phase 3 TRIUMPH-1 trial, people on the 12 mg dose of retatrutide, which activates the GIP, GLP-1 and glucagon receptors, lost an average of 28.3 percent of body weight (70.3 lbs) over 80 weeks, with 45.3 percent losing at least 30 percent, a level long associated with bariatric surgery. All doses met primary and key secondary endpoints for obesity.

• 12 mg dose: 28.3% mean weight loss (70.3 lbs) at 80 weeks; 45.3% achieved ≥30% weight loss
• 4 mg dose: 19.0% mean weight loss (47.2 lbs) with lower observed adverse event discontinuation rate
• Extended follow-up to 104 weeks in high-BMI group: 30.3% mean weight loss (85.0 lbs)
• All doses (4, 9, 12 mg) met primary endpoints; GIP/GLP-1/glucagon triple receptor agonist